Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years and ≤ 45 years of age.

• Presence of lesion suspicious for benign breast disease on mammography and planned breast biopsy Had a live birth ≤5 years prior to pre-registration.

• Provide written informed consent.

• Ability to complete questionnaire(s) by themselves or with assistance.

• Willingness to provide mandatory blood and urine specimens for correlative research.

• Willingness to provide mandatory tissue specimens for correlative research.

• Pre-registration - Exclusion criteria.

• History of breast cancer including DCIS.

• Received systemic treatment for any other cancer at any time Currently taking aspirin or other NSAIDS (no doses within ≤ 5 days prior to pre-registration and no more than four doses within ≤30 days prior to pre-registration).

• Currently taking other agents for the prevention of breast cancer

• Currently taking anticoagulants.

• Contraindication for aspirin use.

Registration - Inclusion Criteria.

• Age ≥ 18 years and ≤45 years of age.

• Histological confirmation of benign breast disease (i.e., no evidence of DCIS or invasive cancer).

• Registration must be completed ≤30 days after pre-registration biopsy performed for this study.

• The following laboratory values obtained ≤30 days prior to registration:

• Hemoglobin ≥ 9.0 g/dL.

• Platelet count ³100,000/mm3.

• Serum creatinine ≤ 2.0 mg/dl.

• Provide written informed consent.

• Ability to complete questionnaire(s) by themselves or with assistance.

• Willingness to provide mandatory blood and urine specimens for correlative research.

• Willingness to provide mandatory tissue specimens for correlative research.

• Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).

Exclusion Criteria:

• No research tissue collected during pre-registration biopsy performed for this study.

• Currently taking aspirin or other NSAIDS (no doses within ≤5 days prior to registration and no more than four doses within ≤30 days prior to registration).

• Co-morbid illnesses/conditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

• Contraindication to aspirin use.

• Currently taking anticoagulants.

• Any malignancy requiring systemic therapy.